Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Mallinckrodt
Julphar
Medtronic
Colorcon
US Department of Justice
Healthtrust
Boehringer Ingelheim
Chinese Patent Office

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,143,908

« Back to Dashboard

Which drugs does patent 7,143,908 protect, and when does it expire?

Patent 7,143,908 protects ADVAIR HFA, FLOVENT HFA, and VENTOLIN HFA, and is included in three NDAs.

Protection for ADVAIR HFA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighteen patent family members in seven countries.
Summary for Patent: 7,143,908
Title:Indicating device
Abstract:A device for dispensing metered dosages of a substance from a container includes a dispenser housing having a longitudinally extending cavity defined at least in part by a wall and a support block spaced from the wall. The container is disposed in the cavity of the dispenser housing and is container reciprocally moveable within the dispenser housing along a longitudinal axis. An indicating device is disposed in the dispenser housing and includes an annular member disposed around a first end of the container with a valve stem of the container extending beyond the annular member. The indicating device includes at least one indicator member rotatable about an axis of rotation. At least a portion of the indicating device is fixedly connected to the container and is reversibly removable with the container from the dispenser housing.
Inventor(s): Blacker; Richard (London, CA), Engelbreth; Daniel K. (London, CA), Schmidt; James N. (London, CA)
Assignee: Trudell Medical International (London, CA)
Application Number:11/372,441
Patent Claim Types:
see list of patent claims
Device; Use;

Drugs Protected by US Patent 7,143,908

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Glaxo Grp Ltd ADVAIR HFA fluticasone propionate; salmeterol xinafoate AEROSOL, METERED;INHALATION 021254-001 Jun 8, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Glaxo Grp Ltd ADVAIR HFA fluticasone propionate; salmeterol xinafoate AEROSOL, METERED;INHALATION 021254-002 Jun 8, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Glaxo Grp Ltd ADVAIR HFA fluticasone propionate; salmeterol xinafoate AEROSOL, METERED;INHALATION 021254-003 Jun 8, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Glaxo Grp Ltd FLOVENT HFA fluticasone propionate AEROSOL, METERED;INHALATION 021433-003 May 14, 2004 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,143,908

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,984,826 Indicating device ➤ Sign Up
6,435,372 Delivery system for a medicament and method for the assembly thereof ➤ Sign Up
7,575,130 Indicating device ➤ Sign Up
6,142,339 Aerosol dispensing device ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Deloitte
Queensland Health
Teva
Medtronic
Dow
Cerilliant
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.